


สถานการณ์เชื่อด้อย่าต้านจุดชีพ ปี 2000-2022(12M)

ศูนย์เฝ้าระวังเชื่อด้อย่าต้านจุดชีพแห่งชาติ (NARST)
สถาบันวิจัยวิทยาศาสตร์สาธารณสุข กรมวิทยาศาสตร์การแพทย์


<http://narst.dmsc.moph.go.th>

Antimicrobial Resistance rates of *Enterococcus* spp. by year

(NARST - 68 hospitals, 12M 2022)




Rate of vancomycin resistant enterococci



Percent resistance of *E. faecium*, *E. faecalis* to vancomycin

E. faecium


OPD IPD ICU



Vancomycin


E. faecalis

OPD IPD ICU





Vancomycin

Antimicrobial Resistance rates of *Staphylococcus spp.* by year (NARST - 68 hospitals, 12M 2022)




Percent isolates of Methicillin Resistance *S. aureus* (MRSA) and Methicillin Resistance *Staphylococcus* coagulase negative (MRSCN)




Antimicrobial Resistance rates of *S. pneumoniae* by year

(NARST - 68 hospitals, 12M 2022)




Susceptibility of *S. pneumoniae* by specimen

Penicillin G (Oxacillin)




Erythromycin




Antimicrobial Resistance rates of *Acinetobacter* spp. by year

(NARST – 68 hospitals, 12M 2022)



Antimicrobial Resistance rates of *P. aeruginosa* by year (NARST - 68 hospitals, 12M 2022)

- Piperacillin/Tazobactam
- Ceftazidime
- Imipenem
- Norfloxacin (UTI)
- Ciprofloxacin
- Amikacin
- Colistin (MIC)




12M 2022 68H

NARST data


CLSI 2019 ไม่กำหนดให้วาง Norfloxacin

Carbapenem Resistance in *Acinetobacter* spp. and *Pseudomonas aeruginosa*


Acinetobacter spp.




Pseudomonas aeruginosa




Percent resistance of *A. calcoaceticus-baumannii* complex to Imipenem



Antimicrobial Resistance rates of *E. coli* by year (NARST - 68 hospitals, 12M 2022)




Antimicrobial Resistance rates of *K. pneumoniae* by year (NARST - 68 hospitals, 12M 2022)



ESBL producing *E. coli*


Cefotaxime $R_{\leq 27}$

■ ESBL by screen test



Ceftazidime $R_{\leq 22}$


■ ESBL by screen test



ESBL producing *K. pneumoniae*


Cefotaxime R_{≤27}

■ ESBL by screen test




Ceftazidime R_{≤22}


■ ESBL by screen test




Percentage Resistance of *E. coli* and *K. pneumoniae*



Carbapenem Resistance in *E. coli* and *K. pneumoniae*




Percent resistant of **Non-typhoidal Salmonella** isolated from **Blood**, 2000-2022 (12M)




Percent resistant of *Non-typhoidal Salmonella* isolated from **Stool & Rectal swab**, 2000-2022 (12M)

%R




Percent resistant of Colistin (2015-2022)



Antimicrobial Resistance rates of *S. pneumoniae*

Meningitis



Non meningitis

